The research team, led by Hugo Belna of the Department of Intensive Care Medicine and Hyperbaric Medicine at CHU d’Angers, together with hematologist Corentin Orvain and colleagues, set out to answer a deceptively simple question: if a transplant recipient’s condition is worsening or improving in the first seventy-two hours of critical illness, does the direction of that change predict whether the patient will die in the ICU? The question matters because intensivists increasingly rely on the concept of a time-limited trial of intensive care, in which support is offered for a defined period and then reassessed. For that strategy to work, clinicians need reliable markers of trajectory, not just snapshots of severity on admission.

The study included 161 allogeneic hematopoietic cell transplantation recipients admitted to the ICU at Angers. To capture the dynamics of organ dysfunction, the investigators used two complementary tools. The first was the Sequential Organ Failure Assessment score, or SOFA, a widely validated composite index that grades dysfunction across six organ systems, including respiration, coagulation, liver function, cardiovascular performance, central nervous system status, and renal function, with each system scored from zero for normal function to four for severe failure. The second was the requirement for organ support, a practical and clinically grounded measure that includes interventions such as invasive mechanical ventilation for respiratory failure and vasoactive drugs or continuous renal replacement therapy for circulatory and kidney failure.

Because a meaningful trajectory can only be measured in patients who remain in the unit long enough for a second assessment, the analysis focused on the subset of 110 patients whose ICU length of stay was at least three days. In this group, the researchers compared the SOFA score recorded on the first day after admission with the score on day three, and calculated a delta SOFA, defined as the difference between the two measurements. They also tracked whether patients required new forms of organ support between days one and three, a change that often signals a decisive turn for the worse even when the numeric score shifts only modestly.

The findings confirmed what many clinicians suspected but had never formally quantified in this specific population. There were significant associations between the SOFA score on day three, the delta SOFA between days one and three, and the emergence of new organ support requirements between those same days, and ICU mortality. In other words, patients whose organ dysfunction remained severe or deepened during the first seventy-two hours, and those who needed to be placed on ventilators, vasopressors, or dialysis machines for the first time during that window, were significantly more likely to die before leaving the unit. The burden of organ failure, and the therapies needed to substitute for failing organs, emerged as the main driver of outcome in these transplant recipients.

Perhaps the most clinically consequential result, however, concerned which measurements carried the greatest predictive weight. The day three SOFA score and any change in organ support requirement between days one and three predicted ICU mortality better than the SOFA score recorded on day one or the delta SOFA itself. This asymmetry is intuitively appealing: a single late measurement that integrates the accumulated damage of the first days of critical illness appears to summarize prognosis more effectively than the arithmetic difference between two early snapshots. A patient admitted with a moderate score who deteriorates rapidly may end up with the same day three score as a patient admitted in worse condition who stabilized, yet their trajectories and their underlying physiology differ in ways the simple delta calculation does not fully capture.

Yet the study also delivers a sobering caveat. While the associations were statistically significant, the overall prediction accuracy of these measures was limited. Neither the day three SOFA score nor the trajectory of organ support could reliably separate survivors from non-survivors at the level of the individual patient. For clinicians hoping that a simple two-day score might provide a defensible threshold for continuing or withdrawing intensive support, the message is one of caution. The trajectory of organ failure is informative at the population level, but it is not precise enough to serve as a stand-alone decision rule for an individual bedridden patient whose family is asking whether more days in the unit will help.

This limitation has real implications for how the time-limited ICU trial is conducted in allogeneic transplant recipients. The approach, in which support is provided for a fixed period and then reassessed against objective markers, has gained traction precisely because early mortality predictions in this population have historically been so unreliable and so pessimistic. Older studies painted a uniformly bleak picture, leading some centers to deny ICU admission or limit support outright. More recent cohorts, including the one from Angers, suggest that outcomes are more heterogeneous than the older literature implied, and that a meaningful fraction of recipients who develop organ failure can still survive if support is maintained and reversible causes are treated.

The technical details of the study design deserve attention when weighing its conclusions. As a retrospective, single-center analysis, it reflects the practices, case mix, and support capabilities of one French academic hospital, and its findings may not generalize perfectly to centers with different transplantation protocols, donor types, or intensity of care. The restriction of the trajectory analysis to patients staying at least three days also introduces a form of survivor bias, since patients who died within the first forty-eight hours were necessarily excluded from the day one to day three comparisons. The authors acknowledge these constraints, and the study is presented as a brief report intended to generate hypotheses rather than to settle definitively how prognostication should be performed.

What the study does establish is a clearer framework for thinking about critical illness after allogeneic hematopoietic cell transplantation. Organ failure, measured either by the SOFA composite or by the concrete need for mechanical ventilation, vasopressors, or renal replacement therapy, is the dominant determinant of ICU survival, outweighing the mere fact of prior transplantation. Serial assessment over the first three days adds some information, with the day three score and new support requirements outperforming admission values, but the incremental prognostic value of tracking the trajectory is modest. For now, the study supports a pragmatic approach: admit these patients, provide a genuine trial of intensive support, reassess organ function and support needs at seventy-two hours, and combine those objective measurements with clinical judgment, discussions with the hematology team, and the values of patients and families rather than relying on any single score to dictate the limits of care.

Subject of Research: Evolution of organ failures and their prognostic value in allogeneic hematopoietic cell transplantation recipients admitted to the intensive care unit

Article Title: Evolution of organ failures in allogeneic hematopoietic cell transplantation recipients admitted to the intensive care unit

Article References: Belna, H., Taillantou-Candau, M., Kouatchet, A., Moreau, C., Riou, J., Klemencie, M., Francois, S., Thépot, S., Mokeddem, C., Giltat, A., Hunault, M., Asfar, P., Tanguy-Schmidt, A., & Orvain, C. (2026). Evolution of organ failures in allogeneic hematopoietic cell transplantation recipients admitted to the intensive care unit. Annals of Hematology. https://doi.org/10.1007/s00277-026-07306-4

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07306-4

Keywords: allogeneic hematopoietic cell transplantation, intensive care unit, SOFA score, organ failure, organ support, ICU mortality, prognosis, critical care, hematology, mechanical ventilation, renal replacement therapy, time-limited trial